umifenovir (arbidol) for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. antiviral and associated therapy
vs. lopinavir/ritonavir
vs. control
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

ELACOI (Lopinavir/ritonavir), 2020 NCT04252885

umifenovir (arbidol) (n=35) vs. lopinavir/ritonavir (n=34)

randomized controlled trial

Studied treatment

Umifenovir
Arbidol (100mg) (oral, 200mg TID for 7-14 days)

Control treatment

Lopinavir/ritonavir
Lopinavir (200mg) boosted by ritonavir (50mg) (orally administed, twice daily, 500 mg, each time for 7-14 days).

3 arms : lopinavir/ritonavir; arbidol and standard care

Patients

COVID-19 mild to moderate

Method

Open-label

China, single center

Remark

No deaths occurred.

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open